Table 4.
Summary of mean domain scores of Guidelines according to AGREE II
| NO | Guideline title | Domain 1 (scope and purpose) | Domain 2 (stakeholder involvement) | Domain 3 (rigor of development) | Domain 4 (clarity of presentation) | Domain 5 (applicability) | Domain 6 (editorial independence) | Total score mean | Overall quality | Overall recommendation (to use guideline) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chemotherapy extravasation guideline | 78.89%*(acceptable) | 94.44%*(good) | 78.33%*(acceptable) | 94.44%*(good) | 80%*(good) | 40%(low) | 76.96% | High | Yes (3 reviewers)Yes with modifications(2 reviewers) |
| 2 | Guideline for the management of extravasation of a cytotoxic agentor a monoclonal antibody used in the treatment of malignantdisease | 78.89%*(acceptable) | 94.44%*(good) | 86.25%*(good) | 98.89%*(good) | 85%*(good) | 36.67%(very low) | 81.16% | High | Yes (3 reviewers)Yes with modifications(2 reviewers) |
| 3 | Guideline for the Management of Extravasation | 72.22%*(acceptable) | 94.44%*(good) | 80.83%*(good) | 74.44%*(acceptable) | 95%*(good) | 45%(low) | 76.96% | High | Yes (2 reviewers)Yes with modifications(3 reviewers) |
| 4 | Clinical Guideline For The Management Of Extravasation Of Cytotoxic Drugs In Adults | 96.67%*(good) | 95.56%*(good) | 80.42%*(good) | 95.56%*(good) | 92.50%*(good) | 100%*(good) | 82.46% | High | Yes (4 reviewers)Yes with modifications(1 reviewer) |
| 5 | Guidelines for the Management ofExtravasation of a Systemic Anti-Cancer Therapy including Cytotoxic Agents | 90%*(good) | 85.56%*(acceptable) | 56.67%(low) | 74.44%*(acceptable) | 50.83%(acceptable) | 48.33%(low) | 62.03% | Moderate | Yes (1 reviewer)Yes with modifications(4 reviewers) |
| Total domain score; mean | 83.33%(good) | 92.89%(good) | 76.50%(acceptable) | 87.56%(good) |
* = Total score of domain>60%